In the high-stakes world of biopharmaceutical manufacturing, the most valuable asset is often the one that never makes it into a patent application or a Standard Operating Procedure (SOP). This asset is "tacit knowledge"—the intuitive expertise, refined techniques, and hard-won lessons learned from years at the bench.
As the biopharmaceutical industry increasingly relies on Contract Development and Manufacturing Organizations (CDMOs) to scale production, a critical systemic failure has emerged: the mass migration of processes is leading to the mass evaporation of expertise. When a technology transfer occurs, documented data moves from point A to point B, but the nuanced, "human" element of the process—the why, the how, and the "what if"—frequently stays behind.
The Anatomy of a Knowledge Crisis
Technology transfer is the lifeblood of drug commercialization. It is the bridge between a promising molecule in a pilot plant and a life-saving therapy available at a commercial scale. However, industry experts are sounding the alarm that this bridge is crumbling under the weight of an increasingly outsourced model.
As of 2022, over 86% of biopharma companies outsource at least some portion of their manufacturing activities. While this strategy is designed to mitigate risk and compress development timelines, it has inadvertently created a "knowledge vacuum." When a company offloads its manufacturing to a third party, it is not just transferring a recipe; it is attempting to transfer the soul of the process.
Ryan Chen, director of Product Marketing at ValGenesis, highlights that the pressure to transfer occurs at every juncture of the drug lifecycle. "Technology transfer occurs repeatedly: from CMC (Chemistry, Manufacturing, and Controls) development to first GMP clinical supply, and further down to commercial scale, between manufacturing sites and even post-approval when capacity, network, or process changes are required," Chen explains.
A Chronology of Erosion
The erosion of institutional knowledge in the biopharmaceutical sector is not a sudden catastrophe but a compounding trend driven by three distinct historical shifts.
1. The Retirement Wave (The Brain Drain)
The U.S. labor market is currently witnessing an unprecedented demographic shift, with approximately 11,000 baby boomers reaching retirement age every single day. This is particularly devastating for the biopharma industry, where specialized manufacturing expertise often takes decades to cultivate. As these seasoned veterans retire, they take with them the collective memory of failed experiments, process troubleshooting, and the subtle "feel" for complex biological systems that cannot be captured in a spreadsheet.
2. The Outsourcing Boom
Over the last two decades, the rise of the CDMO model has fundamentally altered the industry’s geography. While this fostered innovation by allowing startups to focus on R&D, it decoupled the innovator from the manufacturer. In the past, internal manufacturing teams worked alongside R&D scientists, allowing for a continuous, osmosis-like transfer of knowledge. Today, that connection is transactional and contract-bound, often restricting the flow of the very information required to ensure product consistency.
3. The 2025 Downsizing
The year 2025 marked a period of significant volatility, with biopharma layoffs rising by 16%. Crucially, manufacturing and CDMO functions were among the hardest hit. When a company reduces its workforce, it doesn’t just lose labor; it loses the "tribal knowledge" that keeps complex production lines running smoothly. Once that expertise is pruned, it is rarely recovered.
The High Cost of "Document-Centric" Blindness
The industry’s reliance on rigid, document-centric quality management systems (QMS) creates a false sense of security. While the ISPE Good Practice Guide on Knowledge Management in the Pharmaceutical Industry notes that tacit knowledge is "arguably underappreciated," the regulatory landscape remains stubbornly focused on explicit data.
There is currently no regulatory framework that mandates specific, robust methods for capturing tacit knowledge. This results in a "compliance-first" culture where, if a parameter isn’t written in a batch record, it is effectively treated as non-existent.
The financial consequences of this approach are staggering. Merck has publicly reported $125 million in value attributable to dedicated knowledge management over a ten-year period. Conversely, when knowledge transfer fails, the costs are not merely theoretical; they manifest in failed batches, regulatory delays, and, most tragically, the potential for reduced efficacy or safety for the end patient.
The Unique Challenge of Advanced Modalities
If small-molecule manufacturing is akin to baking a cake from a reliable mix, cell and gene therapy (CGT) manufacturing is closer to an artisanal craft. The rise of advanced modalities has brought the tacit knowledge gap into sharp relief.
The Sensitivity of Living Systems
Unlike traditional pharmaceuticals, CGT products are biological entities. "Advanced modalities introduce greater biological variability, complex potency assays, aseptic processing requirements, and sensitivity to operator technique," says Chen. Because these products are living cells, they cannot be terminally sterilized. The manufacturing environment is not a closed loop; it is a delicate interaction between biological material and human intervention.
The Human Variable
In CAR-T manufacturing, steps such as cell isolation, expansion, and harvesting are largely manual. A scientist’s manual technique—the speed of a pipette, the angle of a centrifuge, or the subjective interpretation of a flow cytometry result—directly influences the final product’s yield and potency. When these processes are transferred to a new facility or a new CDMO, the original operator’s "technique" is rarely transferred along with the SOP. This leads to "drift," where the therapy produced at the CDMO behaves differently than the therapy produced during clinical trials.
Implications: Building a Resilient Future
The failure to address the tacit knowledge gap is a strategic oversight that threatens the viability of the next generation of medicines. To move forward, the industry must fundamentally rethink how it defines "technology transfer."
Institutionalizing Knowledge Management
Companies must shift from viewing technology transfer as a late-stage operational hurdle to treating it as a core strategic competency. This involves:
- Designing for Transfer: Developing processes that are inherently robust and less dependent on "tribal" operator techniques.
- Knowledge Harvesting: Implementing digital tools that capture not just the "what" (the results) but the "how" (the decision-making process) during the R&D phase. This includes video documentation of manual techniques, detailed logs of failed attempts, and cross-functional "knowledge handovers."
- Analytical Readiness: Investing heavily in analytical tools that can objectively measure the parameters that were previously left to the subjective judgment of experienced operators.
- Strategic Partnerships: Selecting CDMO partners based on "modality expertise" rather than purely on price or capacity. A true partner should be an extension of the innovator’s team, capable of absorbing the nuances of a complex manufacturing process.
The Role of Governance
Strong governance and change-control discipline are not just regulatory requirements; they are essential tools for maintaining knowledge continuity. By embedding knowledge management into the Quality Management System (QMS), firms can create a formal "feedback loop" that preserves the lessons learned from every manufacturing run.
Conclusion: A New Standard of Excellence
As the biopharmaceutical industry pivots toward increasingly personalized and complex therapies, the cost of losing tacit knowledge will only continue to rise. We are currently in an era where the data we have is vast, but the wisdom we retain is shrinking.
The path forward requires a cultural transformation. The industry must move beyond the safety of rigid documentation and embrace a more holistic approach to knowledge—one that values the researcher’s intuition as much as the regulator’s checkbox. Only by bridging the gap between what is written and what is known can the industry ensure that the promise of advanced therapies translates reliably from the laboratory to the patient’s bedside.
In the final analysis, technology transfer is a human endeavor. If we continue to treat it as a mere data-transfer exercise, we risk losing the very innovations we strive to bring to the world.
About the Author
